Vineti provides a commercial, configurable cloud-based Personalized Therapy Management (PTM) platform that integrates logistics, manufacturing, and clinical data for personalized and high-value advanced therapies. The platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic cell therapies, and can be harnessed for drug products requiring companion diagnostics or REMS programs. Vineti serves patients, healthcare providers, and researchers in hundreds of leading medical centers and manufacturing centers worldwide on behalf of biopharmaceutical partners. Co-founded by GE and the Mayo Clinic and led by CEO Amy DuRoss, Vineti is now a fully independent company. The company has offices in San Francisco, Bethesda, Maryland, and Yerevan, Armenia. The new financing will support further expansion of the PTM platform. Vineti provides a cloud-based platform of record that integrates logistics, manufacturing and clinical data to align and orchestrate the cell and gene therapy process. Its configurable software automates and simplifies complex workflows behind individualized therapies and enables integrations with other parts of the therapy ecosystem. The platform is designed to improve product performance as personalized therapies move into mainstream medicine. Led by CEO and co-founder Amy DuRoss, the company targets pharmaceutical partners developing individualized treatments. Vineti plans to use the new funding to extend its technology platform and expand into Europe and the Asia‑Pacific region. Vineti provides a commercial cloud-based platform that integrates logistics, manufacturing and clinical data to support individualized cell therapies. The platform is designed to improve product performance, promote safety and regulatory compliance, and enable faster, broader patient access. Vineti aims to accelerate life-saving treatment delivery for individualized therapies. The company was co-founded by GE and the Mayo Clinic and is led by CEO Amy DuRoss, chief strategy officer Heidi Hagen, CTO Razmik Abnous and chief science officer Malek Faham. It closed a $13.75M Series A and intends to use the proceeds to grow its team. Backers on the round included GE Ventures, Mayo Clinic Ventures, DFJ and LifeForce Capital.

Total raised

$80M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2020